Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 1
From BugSigDB
Reviewed Marked as Reviewed by Folakunmi on 2024-2-13
Source: Figure 2b
Description: Comparsion of partial response/ stable disease and progressive disease in fecal samples of all patients with non-small cell lung cell lung carcinoma (NSCLC) or renal cell carcinoma (RCC) reponse at 3 months of PD-1 monoclonal antibodies (mAB) treatment
Abundance in Group 1: increased abundance in Responders (partial response or stable disease)
